Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Approvals/Philippines FDA/Retacyl 600

Approved

STANDARD

Retacyl 600

Saga Lifesciences Limited🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: d6381960618cbc80
Company: Saga Lifesciences Limited
Type: Standard

Approval Details

Approval Id: d6381960618cbc80
Drug Approval Philippines Name: Retacyl 600
Product Name: Retacyl 600
Registration Number: DRP-14595-03
Brand Name: Retacyl 600
Generic Name: Acetylcysteine
Dosage Form: Powder for Oral Solution
Dosage Strength: 600 mg
Manufacturer: Saga Lifesciences Limited
Importer: Medinova Pharmaceutical Inc
Distributor: Reta Drug
Issuance Date: 24 June 2024
Expiry Date: 20 October 2028
Pharmacologic Category: Mucolytic
Classification: Prescription Drug (Rx)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

d6381960618cbc80

Type

Standard

Back to Philippines FDA Approvals

Retacyl 600 - Philippines FDA Drug Approval Details